Erlotinib-Cisplatin Combination Inhibits Growth and Angiogenesis through c-MYC and HIF-1α in EGFR-Mutated Lung Cancer In Vitro and In Vivo

Combination treatment for non–small cell lung cancer (NSCLC) is becoming more popular due to the anticipation that it may be more effective than single drug treatment. In addition, there are efforts to genetically screen patients for specific mutations in light of attempting to administer specific a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jasmine G., Wu, Reen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351293/
https://www.ncbi.nlm.nih.gov/pubmed/25748238
http://dx.doi.org/10.1016/j.neo.2014.12.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351293/
https://www.ncbi.nlm.nih.gov/pubmed/25748238
http://dx.doi.org/10.1016/j.neo.2014.12.008

Ejemplares similares